Survival for the fittest: guadecitabine in rel/ref AML-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Survival for the fittest: guadecitabine in rel/ref AML

Published:2024-04-23 Issue:8 Volume:8 Page:2018-2019
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Sheehy Joshua¹²³,Lane Steven W.¹²³^ORCID

Affiliation:

1. 1Cancer Care Services, Royal Brisbane and Women’s Hospital, Queensland, Brisbane, Australia

2. 2School of Medicine, University of Queensland, Brisbane, Australia

3. 3Cancer Research Program, QIMR Berghofer Medical Research Institute, Queensland, Brisbane, Australia

Publisher

American Society of Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/8/8/2018/2222900/blooda_adv-2024-012569-c-main.pdf

Reference7 articles.

1. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial;Roboz;Blood Adv,2024

2. Targeted therapy development in acute myeloid leukemia;Totiger;Biomedicines,2023

3. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies;Stomper;Leukemia,2021

4. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study;Fenaux;Blood Adv,2023

5. Azacitidine and venetoclax in previously untreated acute myeloid leukemia;DiNardo;N Engl J Med,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP